Natco Pharma Increases Investment in US Biotechnology Firm eGenesis to $22 Million
Natco Pharma is investing an additional USD 14 million in US-based biotechnology firm eGenesis Inc through its subsidiaries, bringing its total investment to USD 22 million. The investment involves convertible promissory notes from Natco Pharma (Canada) Inc and Natco Pharma South Africa Proprietary Ltd. eGenesis develops genome engineering technology for transplantable organs, including kidney, liver, and heart transplants. In March 2024, eGenesis performed the world's first porcine kidney transplant in a living patient, authorized by the US FDA under the Expanded Access pathway, with positive outcomes reported.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (66/100). Lens Score 44/100.
Outlets measured: businessstandard, businessstandard, news18, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 25 Aug, 07:53 am. Other outlets followed.